JP2009529541A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529541A5
JP2009529541A5 JP2008558554A JP2008558554A JP2009529541A5 JP 2009529541 A5 JP2009529541 A5 JP 2009529541A5 JP 2008558554 A JP2008558554 A JP 2008558554A JP 2008558554 A JP2008558554 A JP 2008558554A JP 2009529541 A5 JP2009529541 A5 JP 2009529541A5
Authority
JP
Japan
Prior art keywords
group
treatment
prevention
pharmaceutical formulation
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063699 external-priority patent/WO2007104053A2/en
Publication of JP2009529541A publication Critical patent/JP2009529541A/ja
Publication of JP2009529541A5 publication Critical patent/JP2009529541A5/ja
Pending legal-status Critical Current

Links

JP2008558554A 2006-03-09 2007-03-09 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤 Pending JP2009529541A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78080006P 2006-03-09 2006-03-09
PCT/US2007/063699 WO2007104053A2 (en) 2006-03-09 2007-03-09 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009529541A JP2009529541A (ja) 2009-08-20
JP2009529541A5 true JP2009529541A5 (https=) 2010-04-30

Family

ID=38371082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558554A Pending JP2009529541A (ja) 2006-03-09 2007-03-09 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤

Country Status (12)

Country Link
US (2) US7951803B2 (https=)
EP (1) EP1991547A2 (https=)
JP (1) JP2009529541A (https=)
KR (1) KR20080107466A (https=)
CN (1) CN101454325A (https=)
AU (1) AU2007222982A1 (https=)
BR (1) BRPI0709007A2 (https=)
CA (1) CA2646429A1 (https=)
EA (1) EA014907B1 (https=)
MX (1) MX2008011525A (https=)
WO (1) WO2007104053A2 (https=)
ZA (1) ZA200807715B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
KR20090075854A (ko) * 2006-10-20 2009-07-09 엔.브이.오가논 ＰＫＣθ 억제제로서의 푸린
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PH12012501662A1 (en) * 2010-02-18 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Triazolo [4,5 - b] pyridin derivatives
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33246A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
WO2014072244A1 (en) 2012-11-09 2014-05-15 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
CA2929742C (en) 2013-12-04 2022-09-20 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
EP3140300B1 (en) 2014-05-07 2019-08-14 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
CN106008506B (zh) * 2016-06-27 2018-02-13 山东大学 取代嘌呤类衍生物及其制备方法与应用
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20250289806A1 (en) * 2022-04-28 2025-09-18 University Of Miami Compounds for proliferative disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
ES2150113T3 (es) 1995-04-03 2000-11-16 Novartis Ag Derivados de pirazol y procedimientos para la preparacion de los mismos.
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors
WO2003037362A2 (en) 2001-10-29 2003-05-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN103251953A (zh) * 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
AU2005298637B8 (en) * 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
NZ562468A (en) * 2005-04-05 2009-10-30 Pharmacopeia Inc Purine and imidazopyridine derivatives for immunosuppression
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
KR101443651B1 (ko) * 2005-10-18 2014-09-23 얀센 파마슈티카 엔.브이. Ｆｌｔ-3 키나제의 억제 방법
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
KR20090075854A (ko) * 2006-10-20 2009-07-09 엔.브이.오가논 ＰＫＣθ 억제제로서의 푸린
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20080220256A1 (en) * 2007-03-09 2008-09-11 Ues, Inc. Methods of coating carbon/carbon composite structures

Similar Documents

Publication Publication Date Title
JP2009529541A5 (https=)
WO2007131005A3 (en) Use of organic compounds
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
JP2017527578A5 (https=)
WO2012094636A3 (en) Chemosensory receptor ligand-based therapies
JP2010518061A5 (https=)
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
JP2009530399A5 (https=)
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2013529210A5 (https=)
JP2016040288A5 (https=)
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2010003624A3 (en) Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP2012507535A5 (https=)
JP2014505107A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
EP2579876A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDICT
JP2006525297A5 (https=)
JP2008532974A5 (https=)
JP2014510741A5 (https=)
EP2646032A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND TYPE 2 DIABETES, ADIPOSITAS OR PREDICTES
JP2015516419A5 (https=)